Supernus Pharmaceuticals Reports Officer and Director Changes
Ticker: SUPN · Form: 8-K · Filed: Aug 4, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, governance, compensation
Related Tickers: SUPN
TL;DR
Supernus shuffled its execs and board, updated pay. Watch for strategy shifts.
AI Summary
Supernus Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting changes effective June 16, 2025. The filing details the departure of directors or certain officers, the election of new directors, and the appointment of certain officers, along with updates to compensatory arrangements for these officers.
Why It Matters
Changes in key leadership and compensation structures can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and director roles, especially with compensatory arrangement updates, can introduce uncertainty about future strategy and operational direction.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- June 16, 2025 (date) — Effective date of reported changes
- August 4, 2025 (date) — Filing date of the 8-K
FAQ
Who specifically departed from their roles at Supernus Pharmaceuticals, Inc.?
The filing indicates the departure of directors or certain officers, but does not name the specific individuals in this excerpt.
Were any new directors elected to the board?
Yes, the filing explicitly states the election of directors.
What is the effective date for these reported changes?
The earliest event reported is dated June 16, 2025.
Does the filing provide details on new compensatory arrangements?
Yes, the filing mentions updates to compensatory arrangements for certain officers.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the departure of directors/officers, election of directors, appointment of officers, and changes in compensatory arrangements.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).